Unknown

Dataset Information

Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.


ABSTRACT:

Importance

Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions.

Objective

To assess the efficacy and safety of the topical phosphodiesterase 4 inhibitor PF-07038124 in patients with AD and plaque psoriasis.

Design, setting, and participants

This phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across 4 countries. Eligible patients (aged 18-70 years) had mild to moderate AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area). Data were analyzed until December 15, 2021.

Interventions

Patients were randomized (1:1) to PF-07038124, 0.01%, topical oin

SUBMITTER: Eichenfield LF 

PROVIDER: S-EPMC10733847 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature